Related Experiment Videos
[Three patients with gynaecomastia]
M Walraven1, H J Wilmink, L M de Boer
1Afd. Interne Geneeskunde, Diakonessenhuis Utrecht, Bosboomstraat 1, 3582 KE Utrecht.
Nederlands Tijdschrift Voor Geneeskunde
|May 15, 2004
Summary
Gynecomastia, or male breast enlargement, can signal serious underlying health issues. Thorough medical evaluation is crucial for diagnosing conditions like thyrotoxicosis, Klinefelter
Area of Science:
- Endocrinology
- Oncology
- Reproductive Medicine
Background:
- Gynecomastia, characterized by the enlargement of male breast tissue, can be a symptom of various endocrine and oncological conditions.
- Differential diagnosis of gynecomastia requires a comprehensive approach, considering hormonal imbalances, genetic disorders, and neoplastic processes.
Observation:
- Case 1: A 22-year-old male presented with gynecomastia and thyrotoxicosis secondary to an extensively metastasized extragonadal choriocarcinoma.
- Case 2: A 53-year-old male with Klinefelter syndrome exhibited biochemically obscured hypogonadism due to medication-induced hyperprolactinemia.
- Case 3: A 62-year-old male with acromegaly and secondary hypogonadism presented with gynecomastia due to a mixed pituitary adenoma secreting prolactin and growth hormone.
Findings:
- Extragonadal choriocarcinoma can manifest with gynecomastia due to human chorionic gonadotropin (hCG) production.
- Klinefelter syndrome (47,XXY) and hyperprolactinemia can coexist and contribute to gynecomastia.
- Pituitary adenomas secreting both prolactin and growth hormone are associated with acromegaly, secondary hypogonadism, and gynecomastia.
Implications:
- Gynecomastia necessitates a thorough diagnostic workup to identify potentially life-threatening underlying pathologies.
- Multidisciplinary evaluation involving endocrinologists, oncologists, and geneticists is often required for complex cases.
- Early detection and management of the underlying cause of gynecomastia are critical for patient outcomes.